Wanbury Limited

524212

INE107F01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-30 am EDT			5-day change	1st Jan Change
152.7 ^INR	+1.73%		-4.23%	+15.68%

Apr. 01	Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director	CI
Feb. 21	Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director	CI

Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director

April 01, 2024 at 08:12 am EDT

Wanbury Limited announced that Mr. Narinder Kumar Puri (DIN: 00002226) are retired from the position of the Independent Directors on completion of his second term of Office as an Independent Director of the Company with effect from closing of the business hours on 31 March, 2024 and ceased to be the Independent Director of the Company thereafter.

Latest news about Wanbury Limited

Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director	Apr. 01	CI
Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director	Feb. 21	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 24	CI
Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director	Nov. 18	CI
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-20	CI
Wanbury Limited announced that it expects to receive INR 60 million in funding from Expert Chemicals Pvt. Ltd.	23-10-19	CI
Wanbury Limited Appoints Mohan Kumar Rayana as Whole Time Director	23-08-21	CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Wanbury Limited Approves Issue of Unlisted, Secured Redeemable, Non-Convertible Debentures	23-07-11	CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-07-07	CI
Wanbury Limited Announces Board Changes	23-03-27	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Wanbury Widens Loss in Fiscal Q2	22-11-29	MT
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-28	CI
Wanbury Limited Auditor Raises 'Going Concern' Doubt	22-09-05	CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-06-22	CI
Wanbury Limited Approves Appointment of Non-Executive Independent Directors	22-03-17	CI
Wanbury Limited Approves Board Appointments	22-02-17	CI
Wanbury Limited announced that it expects to receive INR 143.0625 million in funding from Expert Chemicals Pvt. Ltd.	22-02-16	CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-08	CI
Wanbury Limited Announces the Demise of S. K. Bhattacharyya, from the Board of Directors and Committees	22-01-27	CI
Wanbury Swings to Loss in Fiscal Q2	21-11-26	MT
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-25	CI
Wanbury Limited Announces Audited Consolidated Earnings Results for the Year Ended March 31, 2021	21-09-03	CI

Chart Wanbury Limited

Duration

Period

More charts

Company Profile

Wanbury Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. It has approximately 13 API products. It manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The Company's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).

Sector

Pharmaceuticals

Calendar

2024-05-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WANBURY LIMITED	+15.68%	59.91M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.18B
OTSUKA HOLDINGS CO., LTD.	+21.55%	23.23B
SANDOZ GROUP AG	+15.11%	14.6B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-7.99%	6.79B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.31B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B